Makers Laboratories Ltd
Incorporated in 1984, Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. [1]
- Market Cap ₹ 86.9 Cr.
- Current Price ₹ 147
- High / Low ₹ 157 / 94.0
- Stock P/E
- Book Value ₹ 111
- Dividend Yield 0.00 %
- ROCE 1.08 %
- ROE -3.43 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.1.23 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|
| 69 | 127 | 101 | 106 | |
| 60 | 108 | 98 | 104 | |
| Operating Profit | 8 | 19 | 3 | 2 |
| OPM % | 12% | 15% | 3% | 2% |
| 1 | 3 | 2 | 1 | |
| Interest | 2 | 2 | 2 | 2 |
| Depreciation | 5 | 4 | 4 | 5 |
| Profit before tax | 3 | 16 | -1 | -3 |
| Tax % | 50% | 25% | -161% | |
| 1 | 12 | -2 | -4 | |
| EPS in Rs | -0.56 | 8.44 | -8.05 | -8.91 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -120% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 23% |
| 3 Years: | -15% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|
| Equity Capital | 5 | 5 | 6 | 6 |
| Reserves | 49 | 55 | 63 | 60 |
| 21 | 23 | 17 | 15 | |
| 62 | 62 | 66 | 73 | |
| Total Liabilities | 136 | 144 | 152 | 154 |
| 71 | 68 | 85 | 83 | |
| CWIP | 0 | 9 | 0 | 2 |
| Investments | 2 | 0 | 0 | 0 |
| 63 | 66 | 67 | 68 | |
| Total Assets | 136 | 144 | 152 | 154 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| 0 | 18 | -9 | |
| 0 | -22 | 1 | |
| 0 | 0 | 6 | |
| Net Cash Flow | 0 | -3 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|
| Debtor Days | 88 | 39 | 72 |
| Inventory Days | 344 | 166 | 281 |
| Days Payable | 182 | 38 | 91 |
| Cash Conversion Cycle | 250 | 167 | 262 |
| Working Capital Days | 159 | 104 | 140 |
| ROCE % | 15% | 1% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 22 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 19 Apr
- Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended 31st March, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio
The Co’s product portfolio covers a wide range of General Health Therapeutic segments. Its top formulation brands are Duramol (Paracetamol), Artemak-AB (a-ß Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). [1]